Gador S.A. Patent applications |
Patent application number | Title | Published |
20100197935 | CRYSTALLINE FORM OF THE ZOLEDRONIC ACID, A PROCESS TO OBTAIN IT AND THE PHARMACEUTICAL COMPOSITION COMPRISING IT - A method to obtain a new crystalline form of the Zoledronic acid, characterized by its X-rays diffractogram as well as by its spatial atomic distribution in the red crystalline and its curves of thermal analysis. There is also included a method to obtain this crystalline form, which includes the synthesis of the corresponding acid and the pharmaceutical composition this crystalline form comprises. | 08-05-2010 |
20100197931 | CRYSTALLINE FORM OF THE ZOLEDRONIC ACID, A PROCESS TO OBTAIN IT AND THE PHARMACEUTICAL COMPOSITION COMPRISING IT - A new crystalline form of the Zoledronic acid, characterized by its X-rays diffractogram as well as by its spatial atomic distribution in the red crystalline and its curves of thermal analysis. There is also included a method to obtain this crystalline form, which includes the synthesis of the corresponding acid and the pharmaceutical composition this crystalline form comprises. | 08-05-2010 |
20090247491 | COMPOSITION COMPRISING BISPHOSPHONATES FOR PREVENTION AND/OR TREATMENT OF METABOLIC DISEASES OF BONES, PROCESS FOR PREPARING SUCH COMPOSITION AND USE THEREOF - The present invention relates to a composition for prevention and/or treatment of metabolic diseases of bones comprising at least one bisphosphonate; viscosity agents comprising carboxymethylcellulose and xanthan gum; at least one flavouring agent; and purified water; a process for preparing a composition according to the present invention; and use of such a composition for prevention, treatment and/or diagnosis of metabolic diseases of bones, especially for children. | 10-01-2009 |
20090203724 | SOLID AND CRYSTALLINE DUTASTERIDE AND PROCESSES FOR PREPARATION THEREOF - The solid state chemistry of 17β-N-[2,5-bis(trifluoromethyl)phenyl]carbamoyl-4-aza-5-α-androst-1-en-3-one of which the international nonproprietary name is Dutasteride (the active ingredient in products marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) and its process for preparing. The synthetic process comprises formation of the mixed anhydride, its subsequent reaction with 2,5-bis(trifluoromethyl)phenylamine in the presence of an appropriate Lewis catalyst and its isolation, purification and crystallization from acetonitrile/water. | 08-13-2009 |
20090155358 | PHARMACEUTICAL COMPOSITIONS OF SHORT-ACTING HYPNOTIC AGENTS IN MODIFIED-RELEASE FORMS AND THE PROCEDURES TO PREPARE THE MENTIONED FORMULATION - This application refers to a modified-release pharmaceutical composition containing, as the active agent, a short-acting hypnotic agent or a pharmaceutically acceptable salt thereof, comprising two sustained-release pharmaceutical entities, differentiated from each other by a different release rate of the active agent wherein the release of the active agent from one of the entities starts before the release of the active agent from the second entity. | 06-18-2009 |
20080227756 | USE OF BISPHOSPHONATES FOR THE TREATMENT OF OSTEOGENESIS IMPERFECTA - This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average.±.1 DS). Then the administration of the bisphosphonate preparation is interrupted in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bishphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again. The proposed procedure of a period with bisphosphonate followed by another period without the bisphosphonate agent improves fracture resistance, provided that the length of both periods is controlled by defined osteologic variables. | 09-18-2008 |